Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials

INTRODUCTION: Mucopolysaccharidosis type VII (MPS VII, Sly Syndrome) is a progressive, debilitating, ultra-rare lysosomal storage disorder caused by the deficiency of β-glucuronidase (GUS), an enzyme required for breakdown of glycosaminoglycans (GAGs). Vestronidase alfa, a recombinant human GUS, is...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Pharmacokinet
Autores principales: Qi, Yulan, McKeever, Kathleen, Taylor, Julie, Haller, Christine, Song, Wenjie, Jones, Simon A., Shi, Jack
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6451706/
https://ncbi.nlm.nih.gov/pubmed/30467742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-018-0721-y
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares